📣 Incretin-based therapies are changing obesity treatment, but who is able to benefit? Another brilliant and impactful article led by @drmariespreckley.bsky.social ✨ Thank you to Dr Adrian Brown for supporting this work. lnkd.in/ehH8Uw_t @imsepidemiology.bsky.social @ims-mrl.bsky.social

@imsepidemiology.bsky.social’s @drmariespreckley.bsky.social was a keynote panellist at @sbm.org’s 47th Annual Meeting. She examined evolving definitions of success in obesity treatment with incretin-based therapies, highlighting quality of life, sustainability, & patient-centred outcomes.

Delighted to receive this nomination. Thank you! 🙂

IMS Epidemiology, University of Cambridge@imsepidemiology.bsky.social · 3mo ago

Congratulations to @imsepidemiology.bsky.social's @drmariespreckley.bsky.social who was nominated for @cam.ac.uk's Research Culture Celebration 2026 in recognition of her contributions to fostering positive research culture in her team. Nominees were celebrated on 13 May at a party at Kettle's Yard

Fantastic to join the Keynote Panel at the 47th Annual Meeting of the Society of Behavioural Medicine in Chicago ✨ @imsepidemiology.bsky.social

If you’re in Chicago, we’d love to see you at the closing keynote. I’ll be speaking on: “New Tools, Old Questions: How Should We Define Success in Weight and Health?” @imsepidemiology.bsky.social

This was such a great collaboration with @drmariespreckley.bsky.social, Dr Adrian Brown, and Dr Nikki Davis, published in @thelancetendo.bsky.social !

Dr Marie Spreckley@drmariespreckley.bsky.social · 4mo ago

Delighted to see our latest publication in The Lancet Diabetes & Endocrinology: “Prioritising nutrition alongside paediatric obesity management medications”Congratulations to @cararuggiero.bsky.social for leading this important piece: www.thelancet.com/journals/lan...

Delighted to see our latest publication in The Lancet Diabetes & Endocrinology: “Prioritising nutrition alongside paediatric obesity management medications”Congratulations to @cararuggiero.bsky.social for leading this important piece: www.thelancet.com/journals/lan...

Delighted to contribute to the latest Financial Times feature on the growing consumerisation of GLP-1 therapies and the future of obesity treatment. It is important to remember that they remain medical interventions requiring appropriate clinical oversight, support, and equitable access.

Weight-loss drugs and Mars bars: Novo Nordisk’s comeback bid

The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market

ft.com

Nipping at the heels of GLP-1 weight-loss drugs is the growing concern the pounds shed will be rapidly regained. "You don't want to have longer-term unintended consequences, like frailty and muscle loss. We don't want to replace one health concern with another." Read – buff.ly/OTpSvPq

What you need to know before taking weight-loss drugs

Weight-loss drugs are not the easy solution that many people believe, especially if you hope to keep the pounds off in the long-term.

buff.ly

@imsepidemiology.bsky.social’s @drmariespreckley.bsky.social is quoted in a BBC Future’s article, highlighting concerns that a lack of behavioural and lifestyle support for those on weight-loss drugs can lead to further issues. Read the full BBC Future – buff.ly/OTpSvPq

Fantastic to see this new study published in JMIR, led by our PhD student Hao Teng. In this qualitative study, we explored how young adults interact with food and nutrition content on social media, and how this can inform the design of effective interventions. www.jmir.org/2026/1/e89344

Delighted to contribute to this BBC Future piece out today. Ensuring the right support is in place to optimise outcomes is critical, particularly as use increases. www.bbc.co.uk/future/artic... @bbcstudios.bsky.social @imsepidemiology.bsky.social

Wonderful evening presenting on the impact of the cost of living crisis on infant feeding in the first 1,000 days of life. It has been an absolute privilege to work on this important study led by the brilliant @cararuggiero.bsky.social over the past two years. @imsepidemiology.bsky.social

What are the impacts of food insecurity during the first 1,000 days of life? Join @cararuggiero.bsky.social & @drmariespreckley.bsky.social this Thursday at 6 PM for a free in-person Cambridge Festival talk on insights from the SPROUT study. Register buff.ly/SRMHqfN

GLP-1 therapies work, but how do we balance clinical effectiveness with lived experience, equity, and long-term support? Looking forward to discussing this as a keynote panel member at the Society of Behavioral Medicine Annual Meeting in Chicago on 25 April this year. See you there!

Delighted to contribute to this New York Times piece on why weight-loss medications do not work equally well for everyone: www.nytimes.com/2026/03/12/w...

When Weight-Loss Drugs Don’t Work

nytimes.com

What is the impact of food insecurity during the first 1,000 days of life? Join our free in-person @cambridgefestival.bsky.social talk with @cararuggiero.bsky.social & @drmariespreckley.bsky.social 26 March, 6 PM, Old Divinity School, Cambridge Register buff.ly/HGezP5k

The researchers are: Dr @cararuggiero.bsky.social - University of Cambridge (@cam.ac.uk) Dr @drmariespreckley.bsky.social - @cam.ac.uk Dr Nikki Davis - @unisouthampton.bsky.social Dr Adrian Brown - University College London (@ucl.ac.uk) Find out more in our blog - buff.ly/LS68rwH

Researchers from the University of Cambridge, University College London, and the University of Southampton comment on the necessity of keeping nutrition at the heart of management medications for children and adolescents.

Paediatricians in the UK are prescribing obesity management medications e.g. GLP-1s to children and adolescents for whom lifestyle interventions by themselves are not enough. Find out more in our blog - buff.ly/LS68rwH

In our free in-person @cambridgefestival.bsky.social talk @cararuggiero.bsky.social & @drmariespreckley.bsky.social will share insights from their research into impacts of food insecurity during the first 1,000 days of life. 26 March, 6 PM, Old Divinity School, Cambridge Register buff.ly/HGezP5k

Dr Spreckley @drmariespreckley.bsky.social leads the AMPLIFY study that seeks to understand how people experience next-generation weight loss therapies, to help identify the types of information and wrap-around support that are most meaningful and needed in real-world care. buff.ly/835YqxD (4/4)

AMPLIFY

AMPLIFY explores lived experiences to inform how to support individuals using, or having recently stopped using, incretin-based therapies or weight management.

studies.mrc-epid.cam.ac.uk

Just 12 studies examined nutrition & diet alongside drug treatment, and as trials varied widely in their approaches to dietary advice and nutritional assessment, lacking standardised protocols and reporting, it was difficult to reach robust conclusions to inform the optimal support. (3/4)

In a systematic review published today, Dr Marie Spreckley, Dr Cara Ruggiero, and Dr Adrian Brown found a lack of robust evidence surrounding nutritional advice and support and its impact on calorie intake, body composition, protein adequacy, and patient experiences. buff.ly/Az65PyP (2/4)

New @cam.ac.uk and @ucl.ac.uk research finds people prescribed weight loss drugs such as semaglutide and tirzepatid may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss. 🧵 (1/4)

Delighted to share that our latest study examining nutritional considerations when using next-generation obesity weight management medications such as Ozempic and Mounjaro is now published in Obesity Reviews. @cararuggiero.bsky.social @adrianbrown.bsky.social onlinelibrary.wiley.com/doi/10.1111/...

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence

Next-generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence-based nutritional strategies to support safe and ...

onlinelibrary.wiley.com

Dr Marie Spreckley @cam.ac.uk leads the AMPLIFY study, exploring the lived experiences of people using, or who have recently stopped, incretin-based weight loss therapies, to better understand how to support them with information and wrap-around support. Find out more at buff.ly/AxR0QqR (2/2)

AMPLIFY

AMPLIFY explores lived experiences to inform how to support individuals using, or having recently stopped using, incretin-based therapies or weight management.

studies.mrc-epid.cam.ac.uk

"A key strength [of the guidance] is the emphasis on combining medication with behavioural support and on the need for equitable access, rather than presenting drugs as a stand-alone solution." @drmariespreckley.bsky.social comments on new WHO guidance on weight loss drugs. buff.ly/BEypph6 (1/2)

Dr Marie Spreckley is leading the new AMPLIFY study that seeks to understand how people experience next-generation incretin-based therapies, such as semaglutide and tirzepatide, when used for weight management. Read our news post at www.mrc-epid.cam.ac.uk/blog/2025/11... (2/2)

Exploring lived experiences to help shape future care for next-generation weight management medications - MRC Epidemiology Unit

A new study led by Dr Marie Spreckley is exploring the lived experiences of people using next-generation weight management medications. AMPLIFY (Amplifying Meaningful Perspectives and Lived experience...

mrc-epid.cam.ac.uk

"Nutrition must no longer remain a missing pillar in obesity management medication care." @drmariespreckley.bsky.social @cararuggiero.bsky.social & Adrian Brown on lessons from bariatric interventions on nutritional support needed for GLP-1 receptor agonist assisted weight loss therapy. 🧵(1/2)

Dr Marie Spreckley@drmariespreckley.bsky.social · 9mo ago

I am delighted to share our new perspective piece in the International Journal of Obesity: “Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery.” www.nature.com/articles/s41... @cararuggiero.bsky.social @adrianbrown.bsky.social